What is the core reason for the recent clinical update from Imugene (ASX:IMU)?

Imugene (ASX:IMU) released the update because the business recorded a second complete clinical response within 24 hours inside its concurrent combination trial cohort. The patient achieved this result at their Day 28 assessment following progression after previous therapy.

What are the financial details regarding the funding position of Imugene (ASX:IMU)?

Imugene (ASX:IMU) previously reported a cash balance of US$21.9 million at June 30, 2025. The company later strengthened its capital position through a subsequent US$22.5 million share placement.

How is the Imugene (ASX:IMU) clinical trial structured geographically?

Imugene (ASX:IMU) is currently running its broader clinical program across a total of 15 active sites. The company stated that active patient recruitment is ongoing across 10 locations in the United States and five locations in Australia.

What does the immediate timeline look like for the Imugene (ASX:IMU) therapy program?

Imugene (ASX:IMU) previously forecast that an FDA Type B end-of-phase meeting would occur in the final quarter of calendar year 2025. The business also stated it plans to prepare for a pivotal Phase 2 registrational trial during calendar year 2026.

What was the immediate stock market reaction for Imugene (ASX:IMU) following the announcement?

The Imugene (ASX:IMU) share price moved upward following the release of the medical data. The stock finished the trading session at an increased level of $0.14.

Image for illustrative purposes only. Not a real photo.

Imugene records second complete clinical response

Written by Isaac FrancisPublished Jul 2, 2026, 4:15 AM

Imugene registered a second complete response within 24 hours in its ongoing clinical trial cohort.
The company's stock experienced an upward movement following the release of the medical data.
The business is testing whether the combined treatment can restore activity in patients after disease progression.

Clinical-stage biotechnology firm Imugene (ASX:IMU) announced a second complete response within 24 hours in its concurrent combination trial cohort.

This development follows the company's report on the prior day of a first complete response involving a follicular lymphoma patient.

The new patient response occurred at the Day 28 assessment of a mantle cell lymphoma individual whose disease had progressed after earlier therapy.

The company stated that the study is evaluating whether giving the treatment concurrently with an inhibitor can enhance patient activity after initial progression.

Following the announcement, the Imugene share price was up at $0.14.

The broader trial continues active recruitment across 10 clinical sites in the United States and five sites in Australia.

Financial records show the business held a US$22.5 million placement.

Imugene records second complete clinical response

Perguntas frequentes

Ativos relacionados a notícia